Characteristics of 31 patients treated with anti–PD-1 mAbs for relapsed disease after allo-HCT
| . | All patients (N = 31) . | No GVHD after PD-1 (n = 14) . | Developed GVHD after PD-1 (n = 17) . | P . |
|---|---|---|---|---|
| Age (y) at time of allo-HCT, median (range) | 37 (20-68) | 36 (20-56) | 37 (21-68) | .57* |
| Male | 18 (58) | 8 (57) | 10 (59) | 1.0† |
| White | 25 (81) | 10 (71) | 15 (88) | .37† |
| Disease type | .49‡ | |||
| Hodgkin’s lymphoma | 29 (94) | 14 (100) | 15 (88) | |
| Other lymphoma | 2 (6) | 0 | 2 (12) | |
| Donor type | .02‡ | |||
| Matched sibling | 16 (52) | 4 (28) | 12 (71) | |
| Matched unrelated | 10 (32) | 5 (36) | 5 (29) | |
| Mismatch unrelated | 1 (3) | 1 (7) | 0 | |
| Haploidentical related | 4 (13) | 4 (29) | 0 | |
| Peripheral blood graft source | 29 (94) | 12 (86) | 17 (100) | .20‡ |
| Reduced intensity conditioning | 30 (97) | 14 (100) | 17 (94) | 1.0‡ |
| Prior history of GVHD before to PD-1 | 19 (61) | 7 (50) | 12 (71) | .29† |
| aGVHD prior to PD-1 | 6 (19) | 3 (21) | 3 (17) | .79‡ |
| cGVHD prior to PD-1 | 15 (48) | 6 (43) | 9 (53) | .58‡ |
| Receiving systemic IST at time of PD-1 | 8 (26) | 5 (36) | 3 (18) | .41‡ |
| Complete donor cell chimeric (ie, ≥95% T-cell donor cells) | 27 (93)§ | 12 (86) | 15 (88) | 1.0‡ |
| Days from allo-HCT to administration of anti–PD-1, median (range) | 790 (146-3289) | 920 (146-3289) | 740 (196-1902) | .45* |
| PD-1 treatment | 1.0‡ | |||
| Nivolumab | 28 (90) | 13 (93) | 15 (88) | |
| Pembrolizumab | 3 (10) | 1 (7) | 2 (12) | |
| Disease responded (CR 1 PR) to anti–PD-1 treatment | 23 (77)|| | 11 (79) | 12 (71) | .70‡ |
| Complete responders | 15 (50)|| | 6 (43) | 9 (53) | .58† |
| . | All patients (N = 31) . | No GVHD after PD-1 (n = 14) . | Developed GVHD after PD-1 (n = 17) . | P . |
|---|---|---|---|---|
| Age (y) at time of allo-HCT, median (range) | 37 (20-68) | 36 (20-56) | 37 (21-68) | .57* |
| Male | 18 (58) | 8 (57) | 10 (59) | 1.0† |
| White | 25 (81) | 10 (71) | 15 (88) | .37† |
| Disease type | .49‡ | |||
| Hodgkin’s lymphoma | 29 (94) | 14 (100) | 15 (88) | |
| Other lymphoma | 2 (6) | 0 | 2 (12) | |
| Donor type | .02‡ | |||
| Matched sibling | 16 (52) | 4 (28) | 12 (71) | |
| Matched unrelated | 10 (32) | 5 (36) | 5 (29) | |
| Mismatch unrelated | 1 (3) | 1 (7) | 0 | |
| Haploidentical related | 4 (13) | 4 (29) | 0 | |
| Peripheral blood graft source | 29 (94) | 12 (86) | 17 (100) | .20‡ |
| Reduced intensity conditioning | 30 (97) | 14 (100) | 17 (94) | 1.0‡ |
| Prior history of GVHD before to PD-1 | 19 (61) | 7 (50) | 12 (71) | .29† |
| aGVHD prior to PD-1 | 6 (19) | 3 (21) | 3 (17) | .79‡ |
| cGVHD prior to PD-1 | 15 (48) | 6 (43) | 9 (53) | .58‡ |
| Receiving systemic IST at time of PD-1 | 8 (26) | 5 (36) | 3 (18) | .41‡ |
| Complete donor cell chimeric (ie, ≥95% T-cell donor cells) | 27 (93)§ | 12 (86) | 15 (88) | 1.0‡ |
| Days from allo-HCT to administration of anti–PD-1, median (range) | 790 (146-3289) | 920 (146-3289) | 740 (196-1902) | .45* |
| PD-1 treatment | 1.0‡ | |||
| Nivolumab | 28 (90) | 13 (93) | 15 (88) | |
| Pembrolizumab | 3 (10) | 1 (7) | 2 (12) | |
| Disease responded (CR 1 PR) to anti–PD-1 treatment | 23 (77)|| | 11 (79) | 12 (71) | .70‡ |
| Complete responders | 15 (50)|| | 6 (43) | 9 (53) | .58† |
Values represent n (%) of patients unless otherwise indicated. PD-1 indicates nivolumab or pembrolizumab.
IST, immunosuppressive therapy.
Wilcoxon rank sum test.
χ2 test.
Fisher’s exact test.
Two unknown; of the 2 patients with mixed chimera prior to anti–PD-1 treatment, 1 patient developed aGVHD.
One unknown.